JP2022065063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022065063A5 JP2022065063A5 JP2022019435A JP2022019435A JP2022065063A5 JP 2022065063 A5 JP2022065063 A5 JP 2022065063A5 JP 2022019435 A JP2022019435 A JP 2022019435A JP 2022019435 A JP2022019435 A JP 2022019435A JP 2022065063 A5 JP2022065063 A5 JP 2022065063A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- set forth
- region set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 101500027172 Homo sapiens Soluble interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610399254.4A CN107474134B (zh) | 2016-06-08 | 2016-06-08 | 用于结合白细胞介素4受体的抗体 |
| CN201610399254.4 | 2016-06-08 | ||
| PCT/CN2017/087592 WO2017211319A1 (zh) | 2016-06-08 | 2017-06-08 | 用于结合白细胞介素4受体的抗体 |
| JP2018564202A JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Division JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022065063A JP2022065063A (ja) | 2022-04-26 |
| JP2022065063A5 true JP2022065063A5 (enExample) | 2022-06-13 |
Family
ID=60577597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Active JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
| JP2022019435A Pending JP2022065063A (ja) | 2016-06-08 | 2022-02-10 | インターロイキン‐４受容体への結合のための抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564202A Active JP7025356B2 (ja) | 2016-06-08 | 2017-06-08 | インターロイキン‐４受容体への結合のための抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20190177408A1 (enExample) |
| EP (2) | EP3470430B1 (enExample) |
| JP (2) | JP7025356B2 (enExample) |
| KR (2) | KR102502988B1 (enExample) |
| CN (2) | CN107474134B (enExample) |
| AU (2) | AU2017276473B2 (enExample) |
| BR (1) | BR112018074325A2 (enExample) |
| CA (1) | CA3026568A1 (enExample) |
| ES (1) | ES3007134T3 (enExample) |
| IL (1) | IL263268B2 (enExample) |
| MX (1) | MX2018014941A (enExample) |
| MY (1) | MY189035A (enExample) |
| PH (1) | PH12018502544B1 (enExample) |
| SA (1) | SA518400605B1 (enExample) |
| SG (1) | SG11201810855VA (enExample) |
| UA (1) | UA124835C2 (enExample) |
| WO (1) | WO2017211319A1 (enExample) |
| ZA (1) | ZA201808209B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| KR102652133B1 (ko) * | 2018-02-01 | 2024-03-29 | 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 | IL-4Rα 항체 및 그 용도 |
| CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
| MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| CN113101364B (zh) * | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| CN110872349A (zh) * | 2018-09-04 | 2020-03-10 | 三生国健药业（上海）股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
| CN111494626B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
| CN111592597B (zh) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 白介素4受体(il-4r)结合蛋白及其用途 |
| AU2021244266A1 (en) | 2020-03-27 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R antagonist |
| CN113527485B (zh) | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| IL298257A (en) | 2020-05-22 | 2023-01-01 | Regeneron Pharma | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| CN114957472B (zh) * | 2020-06-22 | 2023-10-31 | 南京融捷康生物科技有限公司 | 抗IL-4Rα的单域抗体以及应用和药物 |
| US20230374144A1 (en) * | 2020-09-10 | 2023-11-23 | Staidson (Beijing) Biopharmaceutical Co., Ltd. | Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof |
| AU2021357078A1 (en) | 2020-10-05 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| US20220220211A1 (en) | 2021-01-08 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
| MX2024001189A (es) | 2021-07-26 | 2024-02-27 | Sanofi Biotechnology | Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. |
| AU2022333073A1 (en) | 2021-08-23 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| KR20240099290A (ko) | 2021-10-20 | 2024-06-28 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법 |
| WO2023130010A1 (en) | 2021-12-30 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| KR20240167717A (ko) | 2022-03-02 | 2024-11-27 | 리제너론 파아마슈티컬스, 인크. | 항체 생산을 위한 세포 배양 방법 |
| WO2023215267A1 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Anti-interleukin-4 receptor (il-4r) antibody formulations |
| US20240199688A1 (en) | 2022-05-02 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
| TW202421660A (zh) | 2022-07-08 | 2024-06-01 | 美商再生元醫藥公司 | 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法 |
| EP4580659A1 (en) | 2022-08-29 | 2025-07-09 | Sanofi Biotechnology | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| IL320670A (en) | 2022-11-23 | 2025-07-01 | Regeneron Pharma | Methods for enhancing bone growth by administering an IL-4R antagonist |
| TW202502819A (zh) | 2023-03-22 | 2025-01-16 | 法商賽諾菲生物技術公司 | 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法 |
| KR20250164835A (ko) | 2023-03-27 | 2025-11-25 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여하여 호산구성 위장염을 치료하는 방법 |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025221640A1 (en) | 2024-04-15 | 2025-10-23 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2382891T3 (es) | 2000-05-26 | 2012-06-14 | Immunex Corporation | Uso de anticuerpos IL-4R y sus composiciones |
| CA2543982C (en) * | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| JP2007534305A (ja) * | 2003-11-07 | 2007-11-29 | アムジェン インコーポレイテッド | サル免疫グロブリン配列 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) * | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20110008326A1 (en) * | 2008-04-02 | 2011-01-13 | Oliver Hill | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| JP5918246B2 (ja) | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9572863B2 (en) * | 2011-12-13 | 2017-02-21 | Pieris Pharmaceuticals Gmbh | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
| RU2690675C2 (ru) | 2012-08-21 | 2019-06-05 | Санофи Байотекнолоджи | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| AU2015209124A1 (en) | 2014-01-27 | 2016-08-18 | Medimmune, Llc | Dipeptidyl peptidase-4 (DPP4/CD26) as a peripheral biomarker of IL-13 activation in asthmatic lung |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| CN108339118A (zh) | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| KR20250044796A (ko) | 2017-10-30 | 2025-04-01 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| US12216129B2 (en) | 2018-11-09 | 2025-02-04 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human IL-4 receptor alpha |
| EP3935085A1 (en) | 2019-03-06 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN111686247B (zh) | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
-
2016
- 2016-06-08 CN CN201610399254.4A patent/CN107474134B/zh active Active
- 2016-06-08 CN CN202110760590.8A patent/CN113372446A/zh not_active Withdrawn
-
2017
- 2017-06-08 ES ES17809758T patent/ES3007134T3/es active Active
- 2017-06-08 MY MYPI2018002201A patent/MY189035A/en unknown
- 2017-06-08 IL IL263268A patent/IL263268B2/en unknown
- 2017-06-08 CA CA3026568A patent/CA3026568A1/en active Pending
- 2017-06-08 PH PH1/2018/502544A patent/PH12018502544B1/en unknown
- 2017-06-08 BR BR112018074325-9A patent/BR112018074325A2/pt unknown
- 2017-06-08 UA UAA201900001A patent/UA124835C2/uk unknown
- 2017-06-08 MX MX2018014941A patent/MX2018014941A/es unknown
- 2017-06-08 JP JP2018564202A patent/JP7025356B2/ja active Active
- 2017-06-08 EP EP17809758.0A patent/EP3470430B1/en active Active
- 2017-06-08 EP EP24177229.2A patent/EP4420671A3/en active Pending
- 2017-06-08 AU AU2017276473A patent/AU2017276473B2/en active Active
- 2017-06-08 KR KR1020227022353A patent/KR102502988B1/ko active Active
- 2017-06-08 KR KR1020197000454A patent/KR102417217B1/ko active Active
- 2017-06-08 SG SG11201810855VA patent/SG11201810855VA/en unknown
- 2017-06-08 WO PCT/CN2017/087592 patent/WO2017211319A1/zh not_active Ceased
- 2017-06-08 US US16/307,930 patent/US20190177408A1/en not_active Abandoned
-
2018
- 2018-12-05 ZA ZA2018/08209A patent/ZA201808209B/en unknown
- 2018-12-06 SA SA518400605A patent/SA518400605B1/ar unknown
-
2020
- 2020-03-04 US US16/809,411 patent/US10774141B2/en active Active
- 2020-08-14 US US16/994,464 patent/US11866491B2/en active Active
-
2022
- 2022-02-10 JP JP2022019435A patent/JP2022065063A/ja active Pending
-
2023
- 2023-11-15 US US18/510,553 patent/US20240190954A1/en active Pending
-
2024
- 2024-08-02 AU AU2024205464A patent/AU2024205464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022065063A5 (enExample) | ||
| US8624002B2 (en) | Prostaglandin E2 binding proteins and uses thereof | |
| ES2817756T3 (es) | Proteínas de unión a interleuquina-13 | |
| CN108350070B (zh) | 胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法 | |
| CN102958537B (zh) | TNF-α结合蛋白 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| JP2008527989A5 (enExample) | ||
| JP2011508592A5 (enExample) | ||
| CN110105451B (zh) | IL-4Rα抗体及其用途 | |
| JP2010500005A5 (enExample) | ||
| CN107428828A (zh) | Tslp结合蛋白 | |
| MX2014004980A (es) | Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17. | |
| KR20190107184A (ko) | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2009533020A5 (enExample) | ||
| JP2009523154A5 (enExample) | ||
| JP2016517277A (ja) | ＴＮＦαに対して指向された二重特異的結合タンパク質 | |
| TW201305214A (zh) | 與人類間白素－１８結合之抗體，及其製法及用途 | |
| JP2011527579A5 (enExample) | ||
| JP2016522793A (ja) | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 | |
| TW202140550A (zh) | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 | |
| JP2022554249A (ja) | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合抗体の乾燥粉末製剤及びその使用方法 | |
| JPWO2021170020A5 (enExample) | ||
| WO2022007965A1 (zh) | 一种抗IgE的工程化抗体及其应用 | |
| JPWO2022040345A5 (enExample) | ||
| RU2019100002A (ru) | Антитело для связывания с рецептором интерлейкина 4 |